Logo image of SURG

SURGEPAYS INC (SURG) Stock Fundamental Analysis

NASDAQ:SURG - Nasdaq - US86882L2043 - Common Stock - Currency: USD

2.91  -0.03 (-1.02%)

After market: 3 +0.09 (+3.09%)

Fundamental Rating

3

Taking everything into account, SURG scores 3 out of 10 in our fundamental rating. SURG was compared to 21 industry peers in the Wireless Telecommunication Services industry. SURG has a bad profitability rating. Also its financial health evaluation is rather negative. SURG is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURG has reported negative net income.
SURG had a negative operating cash flow in the past year.
SURG had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SURG reported negative operating cash flow in multiple years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of SURG (-348.50%) is worse than 95.24% of its industry peers.
With a Return On Equity value of -696.64%, SURG is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -348.5%
ROE -696.64%
ROIC N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

SURG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SURG has more shares outstanding
The number of shares outstanding for SURG has been increased compared to 5 years ago.
Compared to 1 year ago, SURG has a worse debt to assets ratio.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -9.47, we must say that SURG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.47, SURG is not doing good in the industry: 95.24% of the companies in the same industry are doing better.
SURG has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
SURG has a better Debt to Equity ratio (0.24) than 90.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Altman-Z -9.47
ROIC/WACCN/A
WACC9.02%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 1.72 indicates that SURG should not have too much problems paying its short term obligations.
SURG's Current ratio of 1.72 is amongst the best of the industry. SURG outperforms 85.71% of its industry peers.
SURG has a Quick Ratio of 1.41. This is a normal value and indicates that SURG is financially healthy and should not expect problems in meeting its short term obligations.
SURG has a better Quick ratio (1.41) than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.41
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for SURG have decreased strongly by -342.61% in the last year.
SURG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -70.08%.
Measured over the past years, SURG shows a quite strong growth in Revenue. The Revenue has been growing by 18.83% on average per year.
EPS 1Y (TTM)-342.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-642.86%
Revenue 1Y (TTM)-70.08%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-66.35%

3.2 Future

SURG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.97% yearly.
SURG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 83.41% yearly.
EPS Next Y82.56%
EPS Next 2Y45.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year58.23%
Revenue Next 2Y83.41%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M 200M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 1 -1 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SURG. In the last year negative earnings were reported.
SURG is valuated reasonably with a Price/Forward Earnings ratio of 9.51.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SURG indicates a somewhat cheap valuation: SURG is cheaper than 71.43% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, SURG is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.51
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

SURG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SURG's earnings are expected to grow with 45.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.97%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SURG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (7/18/2025, 8:14:14 PM)

After market: 3 +0.09 (+3.09%)

2.91

-0.03 (-1.02%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners9.38%
Inst Owner Change-0.89%
Ins Owners31.21%
Ins Owner Change1.2%
Market Cap59.39M
Analysts80
Price Target9.18 (215.46%)
Short Float %1.99%
Short Ratio1.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.14%
Min EPS beat(2)-304.04%
Max EPS beat(2)-60.24%
EPS beat(4)0
Avg EPS beat(4)-339.26%
Min EPS beat(4)-824.37%
Max EPS beat(4)-60.24%
EPS beat(8)2
Avg EPS beat(8)-155.49%
EPS beat(12)4
Avg EPS beat(12)-62.05%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.22%
Min Revenue beat(2)-14.86%
Max Revenue beat(2)14.43%
Revenue beat(4)1
Avg Revenue beat(4)-12.18%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)14.43%
Revenue beat(8)2
Avg Revenue beat(8)-8.53%
Revenue beat(12)4
Avg Revenue beat(12)-6.55%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.86%
PT rev (3m)33.33%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-225%
EPS NY rev (1m)0%
EPS NY rev (3m)-515.38%
Revenue NQ rev (1m)-13.41%
Revenue NQ rev (3m)-15.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.51
P/S 1.48
P/FCF N/A
P/OCF N/A
P/B 7.58
P/tB 18.41
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)0.31
Fwd EY10.52%
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS1.96
BVpS0.38
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -348.5%
ROE -696.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.87%
ROA(5y)-71.76%
ROE(3y)-79.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover2.56
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.41
Altman-Z -9.47
F-Score2
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-342.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-642.86%
EPS Next Y82.56%
EPS Next 2Y45.97%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-70.08%
Revenue growth 3Y6.01%
Revenue growth 5Y18.83%
Sales Q2Q%-66.35%
Revenue Next Year58.23%
Revenue Next 2Y83.41%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-421.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-591.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-562.95%
OCF growth 3YN/A
OCF growth 5YN/A